Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia.

MLA

Pankowicz, Francis P., et al. “Reprogramming Metabolic Pathways in Vivo with CRISPR/Cas9 Genome Editing to Treat Hereditary Tyrosinaemia.” Nature Communications, vol. 7, Aug. 2016, p. 12642. EBSCOhost, https://doi.org/10.1038/ncomms12642.

APA

Pankowicz, F. P., Barzi, M., Legras, X., Hubert, L., Mi, T., Tomolonis, J. A., Ravishankar, M., Sun, Q., Yang, D., Borowiak, M., Sumazin, P., Elsea, S. H., Bissig-Choisat, B., & Bissig, K.-D. (2016). Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nature Communications, 7, 12642. https://doi.org/10.1038/ncomms12642

Chicago

Pankowicz, Francis P, Mercedes Barzi, Xavier Legras, Leroy Hubert, Tian Mi, Julie A Tomolonis, Milan Ravishankar, et al. 2016. “Reprogramming Metabolic Pathways in Vivo with CRISPR/Cas9 Genome Editing to Treat Hereditary Tyrosinaemia.” Nature Communications 7 (August): 12642. doi:10.1038/ncomms12642.